TRADE REMEDIES | 2026-07-11
Section 301 Germany Pharmaceutical Pricing Investigation
On June 18, 2026, the Office of the United States Trade Representative opened a Section 301 investigation into Germany's alleged suppression of innovative drug prices, a proceeding that could reshape transatlantic trade and directly affects California's life sciences economy and its importers of German goods.
By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published
On June 18, 2026, the Office of the United States Trade Representative opened a Section 301 investigation into Germany's persistent underpayment for innovative pharmaceutical products, and a formal notice announcing the inquiry, scheduling a public hearing, and requesting public comments followed in the Federal Register on June 24. The investigation asks whether Germany, through the design of its statutory health insurance and drug pricing system, holds the prices it pays for breakthrough medici
Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.
Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301